Welcome to our dedicated page for Cabaletta Bio SEC filings (Ticker: CABA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cabaletta Bio’s latest 10-K can read like an immunology textbook—dense tables on CARTA and CAART trial cohorts, layered milestone clauses, and pages of manufacturing risk factors. If you have ever searched “Cabaletta Bio SEC filings explained simply” or hunted for dosing data buried deep within, you know the challenge. Stock Titan turns those hundreds of pages into concise intelligence you can act on.
Our AI-powered summaries extract essentials from every Cabaletta Bio quarterly earnings report 10-Q filing, flagging R&D cash burn and RESET trial updates. Real-time alerts capture Cabaletta Bio insider trading Form 4 transactions the moment they hit EDGAR, so you never miss a Cabaletta Bio Form 4 insider transactions real-time disclosure. Need a Cabaletta Bio annual report 10-K simplified, a quick Cabaletta Bio earnings report filing analysis, or clarity on a sudden Cabaletta Bio 8-K material events explained? Ask the platform—understanding Cabaletta Bio SEC documents with AI becomes effortless.
- Pipeline progress – track clinical milestones straight from 8-K trial announcements.
- Capital strategy – examine collaboration revenue, at-the-market offerings, and cash runway inside each 10-Q.
- Insider sentiment – monitor Cabaletta Bio executive stock transactions Form 4 and Cabaletta Bio proxy statement executive compensation for context.
Every filing type—10-K, 10-Q, 8-K, S-1, and more—is updated in seconds, complete with expert commentary. Spend minutes, not weekends, staying ahead of Cabaletta Bio disclosures.
Cabaletta Bio (CABA) filed a Schedule 13G disclosing that Citadel Advisors LLC, Citadel Securities LLC, related entities and founder Kenneth Griffin collectively own 4,818,560 common shares, or approximately 5.2 % of the company’s 92.94 million shares outstanding.
Citadel Advisors–managed funds hold 4,687,280 shares, while market-making affiliate Citadel Securities holds 131,280 shares. All voting and dispositive power is reported as shared; none of the reporting persons has sole authority. The 5 % threshold was reached on 12 June 2025, triggering the filing. No additional financial results, risk factors, or strategic initiatives are included.
FAQ
What is the current stock price of Cabaletta Bio (CABA)?
What is the market cap of Cabaletta Bio (CABA)?
What is the primary focus of Cabaletta Bio?
What distinguishes Cabaletta Bio's technology?
Which autoimmune diseases are being targeted by their clinical programs?
How does the clinical trial design support their development strategy?
What is the mechanism of action of their lead product candidate?
How is Cabaletta Bio positioned in the broader biotech industry?
What role do manufacturing and process innovations play?
How does Cabaletta Bio demonstrate its expertise and trustworthiness?
